Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision immune protease inhibitors for the treatment of inflammatory and fibrotic diseases. The company’s proprietary platform enables selective targeting of key proteases involved in immune cell regulation, with the goal of modulating disease pathways and reducing systemic side effects typically associated with broad-spectrum immunosuppression.

Upstream Bio’s pipeline comprises multiple programs in clinical development, including candidates aimed at addressing chronic pulmonary and autoimmune conditions characterized by dysregulated neutrophil and macrophage activity. Research and development efforts leverage deep insights into protease biology to pursue indications with high unmet medical need and to optimize therapeutic profiles across patient populations.

Since its inception, Upstream Bio has established collaborations with academic institutions and industry partners to advance its drug candidates. The company is headquartered in the United States and is exploring opportunities for global patient access through strategic licensing and partnership agreements.

Key Stats

• Today's Range: $10.63 to $11.36
• 50-Day Range: $8.56 to $11.84
• 52-Week Range: $5.14 to $29.46
• Volume: 225,652 shs
• Average Volume: 351,241 shs
• Market Capitalization: $576.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.50
• Consensus Rating: Buy

UPB Stock Analysis - Frequently Asked Questions

How have UPB shares performed this year?

Upstream Bio's stock was trading at $16.44 on January 1st, 2025. Since then, UPB shares have decreased by 34.8% and is now trading at $10.72.

How were Upstream Bio's earnings last quarter?

Upstream Bio, Inc. (NASDAQ:UPB) released its earnings results on Tuesday, May, 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The firm had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million.

When did Upstream Bio IPO?

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

How do I buy shares of Upstream Bio?

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Upstream Bio: $56.50
• High Price Target: $75.00
• Low Price Target: $38.00
• Potential Upside/Downside: +427.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 47.43
• Quick Ratio: 47.43

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 243.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.77 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 53,790,000
• Free Float: 46,500,000
• Market Cap: $576.63 million
• Optionable: N/A
• Beta: N/A